v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 28, 2013
Sep. 29, 2012
Sep. 24, 2011
Operating activities      
Net (loss) income $ (1,172,838) $ (73,634) $ 157,150
Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
Depreciation 95,518 71,851 68,946
Amortization 420,492 273,900 235,790
Non-cash interest expense 81,177 74,974 76,814
Stock-based compensation expense 52,307 40,572 35,472
Excess tax benefit related to equity awards (7,439) (6,206) (3,652)
Deferred income taxes (197,983) (155,192) (48,107)
Gain on sale of intellectual property (53,884) (12,424) (84,502)
Debt extinguishment loss 9,209 42,347 29,891
Fair value adjustments to contingent consideration 11,310 38,466 (8,016)
Fair value write-up of inventory sold 52,397 19,918 3,298
Impairment of goodwill 1,117,369 5,826  
Impairment of intangible assets 1,714    
Asset impairment charges 7,667 16,901  
Acquired in-process research and development    4,500  
Cost method equity investment impairment 6,438   2,445
Gain on sale of cost-method equity investment (1,972)    
Loss on disposal of property and equipment 4,925 3,809 2,639
Other 2,923 (3,568) 1,093
Changes in operating assets and liabilities, excluding the effect of acquisitions:      
Accounts receivable 4,102 (11,005) (17,131)
Inventories 25,165 (12,174) (32,158)
Prepaid income taxes 25,100 6,071 (6,154)
Prepaid expenses and other assets 871 69,806 (471)
Accounts payable (6,406) 3,768 2,589
Accrued expenses and other liabilities 2,335 (41,017) 40,569
Deferred revenue 13,325 12,733 (481)
Net cash provided by operating activities 493,822 370,222 456,024
Investing activities      
Acquisition of businesses, net of cash acquired (6,273) (3,762,403) (198,744)
Payment of additional acquisition consideration (16,808) (9,784) (19,660)
Proceeds from sale of business, net of cash transferred 85,134   2,267
Proceeds from sale of intellectual property 60,000 12,500 13,250
Purchase of property and equipment (48,954) (33,149) (27,785)
Increase in equipment under customer usage agreements (41,176) (45,624) (27,878)
Purchase of licensed technology and other intangible assets     (3,021)
Purchase of insurance contracts (4,000)   (5,322)
Acquisition of in-process research and development assets    (4,500)  
Sale of cost method investment 2,104    
Purchases of cost method investments (3,725) (250) (99)
(Increase) decrease in other assets (7,548) (7,574) 405
Net cash provided by (used in) investing activities 18,754 (3,850,784) (266,587)
Financing activities      
Proceeds from long-term debt   3,476,320  
Repayment of long-term debt and notes payable (265,000)   (1,362)
Payment of debt issuance costs (9,440) (81,408) (5,327)
Payment of contingent consideration (42,958) (51,680) (4,294)
Payment of deferred acquisition consideration (1,655) (44,223)  
Net proceeds from issuance of common stock pursuant to employee stock plans 75,100 28,594 25,404
Excess tax benefit related to equity awards 7,439 6,206 3,652
Payment of employee restricted stock minimum tax withholdings (12,256) (5,710) (10,399)
Net cash (used in) provided by financing activities (248,770) 3,328,099 7,674
Effect of exchange rate changes on cash and cash equivalents (1,746) 561 (404)
Net increase (decrease) in cash and cash equivalents 262,060 (151,902) 196,707
Cash and cash equivalents, beginning of period 560,430 712,332 515,625
Cash and cash equivalents, end of period $ 822,490 $ 560,430 $ 712,332